Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy NextCure stock in Canada | $7.85
Own NextCure shares in just a few minutes.
NextCure is a biotechnology business based in the US. NextCure stocks (NXTC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.48 – a decrease of 0.38% over the previous week. NextCure employs 90 staff and has a market cap (total outstanding stock value) of $200.4 million.
How to buy NextCure stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: NXTC in this case.
- Research NextCure stocks. The platform should provide the latest information available.
- Buy your NextCure stocks. It's that simple.
What's in this guide?
- Can I buy shares in NextCure?
- Has coronavirus impacted NextCure shares?
- NextCure shares summary
- Compare share dealing platforms
- Is NextCure stock a buy or sell?
- NextCure performance over time
- Can I short NextCure shares?
- NextCure's financials
- How volatile are NextCure shares?
- Does NextCure pay a dividend?
- Other common questions
How has Coronavirus impacted NextCure's stock price?
Since the stock market crash in March caused by coronavirus, NextCure's stock price has had significant negative movement.
Its last market close was $7.85, which is 84.05% down on its pre-crash value of $49.22 and 260.38% down on the lowest point reached during the March crash when the stocks fell as low as $28.29.
If you had bought $1,000 worth of NextCure stocks at the start of February 2020, those stocks would have been worth $742.39 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $180.31.
NextCure stock priceUse our graph to track the performance of NXTC stocks over time.
NextCure stocks at a glance
|Latest market close||$7.85|
|52-week range||$6.82 - $14.4|
|50-day moving average||$7.7977|
|200-day moving average||$9.8692|
|Wall St. target price||$19.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.917|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy NextCure stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
NextCure price performance over time
|1 month (2021-07-02)||-1.75%|
|3 months (2021-05-03)||-8.08%|
|Gross profit TTM||USD$-24,176,000|
|Return on assets TTM||-13.14%|
|Return on equity TTM||-20.58%|
|Market capitalisation||USD$200.4 million|
TTM: trailing 12 months
How to short and sell NextCure stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "NXTC.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 1.0 million NextCure stocks held short by investors – that's known as NextCure's "short interest". This figure is 50.1% up from 687,766 last month.
There are a few different ways that this level of interest in shorting NextCure stocks can be evaluated.
NextCure's "short interest ratio" (SIR)
NextCure's "short interest ratio" (SIR) is the quantity of NextCure stocks currently shorted divided by the average quantity of NextCure stocks traded daily (recently around 348653.37837838). NextCure's SIR currently stands at 2.96. In other words for every 100,000 NextCure stocks traded daily on the market, roughly 2960 stocks are currently held short.
However NextCure's short interest can also be evaluated against the total number of NextCure stocks, or, against the total number of tradable NextCure stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NextCure's short interest could be expressed as 0.04% of the outstanding stocks (for every 100,000 NextCure stocks in existence, roughly 40 stocks are currently held short) or 0.0591% of the tradable stocks (for every 100,000 tradable NextCure stocks, roughly 59 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against NextCure.
Find out more about how you can short NextCure stock.
NextCure stock dividends
We're not expecting NextCure to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
NextCure stock price volatility
Over the last 12 months, NextCure's stocks have ranged in value from as little as $6.82 up to $14.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while NextCure's is -0.514. This would suggest that NextCure's stocks have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, NextCure has bucked the trend.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Stocks similar to NextCure
NextCure in the news
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Stocks That Hit 52-Week Lows On Tuesday
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to invest $1 million
Here are the top 5 ways you should invest $1 million.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.